{"id":"fd52d8a9-ba2f-5596-bb41-0ee8f93bedc0","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-cyp3a4-inhibition","predicate":"decreases_in_recorded_comparison","statement":"Apigenin inhibited recombinant human CYP3A4-dependent nifedipine oxidation with IC50 8.4 ± 1.1 micromolar.","claim_class":"mechanistic","status":"source_recorded","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"4657ae9e-4063-572f-b95a-d174c4213f22","mechanism_event_label":"Apigenin inhibited recombinant human CYP3A4-dependent nifedipine oxidation with IC50 8.4 ± 1.1 micromolar.","subject":{"id":"4425961f-4764-56d3-9887-87e47749379b","slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"},"object":{"id":"54e95ff1-4ffa-5e6f-a4cb-b47e5d2a5bda","slug":"cyp3a4","display_name":"Human cytochrome P450 3A4","entity_type_key":"protein"},"evidence_count":1,"mechanism_event":{"id":"4657ae9e-4063-572f-b95a-d174c4213f22","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-cyp3a4-inhibition-event","event_type":"biochemical_relationship","label":"Apigenin inhibited recombinant human CYP3A4-dependent nifedipine oxidation with IC50 8.4 ± 1.1 micromolar.","description":"### api-cyp3a4-inhibition\n\nApigenin inhibited recombinant human CYP3A4-dependent nifedipine oxidation with IC50 8.4 ± 1.1 micromolar.\nAssay substrate and preincubation conditions determine potency; no universal supplement-dose threshold follows.\nModel and exposure: Baculosomal human CYP3A4 with reductase/cytochrome b5 and NADPH regeneration.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Characterization of the CYP3A4 Enzyme Inhibition Potential of Selected Flavonoids. | 2021 | https://pubmed.ncbi.nlm.nih.gov/34069400/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC8158701/ | https://doi.org/10.3390/molecules26103018 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"4425961f-4764-56d3-9887-87e47749379b","slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"Apigenin concentration series","sequence_order":0,"notes":""},{"entity":{"id":"54e95ff1-4ffa-5e6f-a4cb-b47e5d2a5bda","slug":"cyp3a4","display_name":"Human cytochrome P450 3A4","entity_type_key":"protein"},"role":"measured outcome","stoichiometry":null,"state_label":"decrease","sequence_order":1,"notes":""},{"entity":{"id":"4aba2a5e-8d06-5304-bb01-c0402b225a94","slug":"nadph","display_name":"NADPH","entity_type_key":"small_molecule"},"role":"electron supply in assay","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"Apigenin concentration series\", \"comparator\": \"Enzyme without inhibitor\", \"endpoint\": \"Apigenin inhibited recombinant human CYP3A4-dependent nifedipine oxidation with IC50 8.4 ± 1.1 micromolar.\", \"effect_direction\": \"decrease\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; recorded from source.","entity":null},{"dimension":"experimental_model","value_text":"Baculosomal human CYP3A4 with reductase/cytochrome b5 and NADPH regeneration.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Apigenin collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Apigenin inhibited recombinant human CYP3A4-dependent nifedipine oxidation with IC50 8.4 ± 1.1 micromolar.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Characterization of the CYP3A4 Enzyme Inhibition Potential of Selected Flavonoids. | https://pubmed.ncbi.nlm.nih.gov/34069400/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC8158701/ | https://doi.org/10.3390/molecules26103018","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference api-cyp3a4-inhibition; Assay substrate and preincubation conditions determine potency; no universal supplement-dose threshold follows.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"433bbcce-3b4a-57b2-8470-d9e6925ff0c6","evidence_kind":"source_excerpt","locator":"Lines 848-854","start_line":848,"end_line":854,"excerpt":"### api-cyp3a4-inhibition\n\nApigenin inhibited recombinant human CYP3A4-dependent nifedipine oxidation with IC50 8.4 ± 1.1 micromolar.\nAssay substrate and preincubation conditions determine potency; no universal supplement-dose threshold follows.\nModel and exposure: Baculosomal human CYP3A4 with reductase/cytochrome b5 and NADPH regeneration.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Characterization of the CYP3A4 Enzyme Inhibition Potential of Selected Flavonoids. | 2021 | https://pubmed.ncbi.nlm.nih.gov/34069400/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC8158701/ | https://doi.org/10.3390/molecules26103018 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","model_system":"Baculosomal human CYP3A4 with reductase/cytochrome b5 and NADPH regeneration.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"54eac90b-add1-5f56-9036-d900307c5697","stable_key":"import-ff370329-68a3-573d-96ee-597de78a3967","title":"Apigenin: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"ede6e5c6b91d66b66844f2ff667a7f8303d9ac1281f15dc09db703f7de4da942","revision_id":"b41a39a2-0197-549c-97a5-1765e6696931","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}